Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics BRACAnalysis Approved by Japanese Regulators

NEW YORK – Japan's Ministry of Health, Labor and Welfare has approved Myriad Genetics' BRACAnalysis Diagnostic System for identifying breast cancer patients with germline BRCA1 and BRCA2 mutations. 

The approval allows physicians in Japan to order BRACAnalysis for women with breast cancer who meet certain criteria established by the Japanese Organization of Hereditary Breast and Ovarian Cancer (JBHBOC). Patients who test positive for a deleterious BRCA1/2 mutation may then be recommended for prophylactic surgeries or targeted treatments. 

Myriad will work with commercial partners in Japan to make the test available to patients. 

Japanese regulators have previously approved BRACAnalysis for two other indications. Earlier this year, regulators approved it as a companion diagnostic for the ovarian cancer drug olaparib (AstraZeneca's Lynparza) and last year as a companion test for the same drug for patients with advanced breast cancer. In conjunction with the companion diagnostic approval, Myriad said it would partner with Miraca Group subsidiary SRL, a large laboratory services provider in Japan, to commercialize the test in the country. 

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.